Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands

Open Access

Peer-reviewed

Research Article

Leonoor Wijnans ,

* E-mail: e.wijnans@erasmusmc.nl

Affiliations Erasmus Medical Center, Rotterdam, The Netherlands, Medicines Evaluation Board, Utrecht, The Netherlands
⨯
Jeanne Dieleman,

Affiliation Erasmus Medical Center, Rotterdam, The Netherlands
⨯
Bettie Voordouw,

Affiliation Medicines Evaluation Board, Utrecht, The Netherlands
⨯
Miriam Sturkenboom

Affiliation Erasmus Medical Center, Rotterdam, The Netherlands
⨯

Reader Comments (0)

Influenza
Is the Subject Area "Influenza" applicable to this article?

Thanks for your feedback.
Vaccination and immunization
Is the Subject Area "Vaccination and immunization" applicable to this article?

Thanks for your feedback.
Vaccines
Is the Subject Area "Vaccines" applicable to this article?

Thanks for your feedback.
Netherlands
Is the Subject Area "Netherlands" applicable to this article?

Thanks for your feedback.
Pandemics
Is the Subject Area "Pandemics" applicable to this article?

Thanks for your feedback.
Swine influenza
Is the Subject Area "Swine influenza" applicable to this article?

Thanks for your feedback.
Cohort studies
Is the Subject Area "Cohort studies" applicable to this article?

Thanks for your feedback.
Reverse transcriptase-polymerase chain reaction
Is the Subject Area "Reverse transcriptase-polymerase chain reaction" applicable to this article?

Thanks for your feedback.